Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
39 studies found for:    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Show Display Options
RSS Create an RSS feed from your search for:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: 10% liquid formulation of human immunoglobulin
2 Unknown  Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
3 Active, not recruiting Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP);   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Biological: IgPro20
4 Completed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions: Biological: IgPro20;   Biological: Placebo;   Biological: IgPro10
5 Completed Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP;   Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: lipoic acid
6 Active, not recruiting Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: hematopoietic stem cell transplantation
7 Withdrawn High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Cyclophosphamide
8 Completed Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: NPB-01
9 Recruiting Subcutaneous Immunoglobulin for CIDP
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Immune Globulin Subcutaneous (Human)
10 Recruiting IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Intravenous Immunoglobulin
11 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Demyelinating Diseases;   Paraproteinemias
Intervention: Drug: intravenous immunoglobulin (IVIg)
12 Completed Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod;   Drug: Placebo Comparator
13 Recruiting sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Procedure: Lumbar puncture;   Procedure: Blood sample
14 Completed Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
15 Completed Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
16 Completed
Has Results
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
17 Recruiting Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Biological: HYQVIA
18 Recruiting Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Condition: CIDP
Intervention: Other: CIDP treated (IVIG)
19 Completed Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Drug: Subcutaneous immunoglobulin
20 Unknown  Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
Condition: Chronic Inflammatory Demyelinating Neuropathy
Intervention: Drug: Alemtuzumab infusion

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.